分子顯影劑的全球市場(～2028年)

本報告提供全球分子顯影劑市場調查，市場概要，市場趨勢，及企業簡介等整體性資訊。

目錄

• 摘要整理
• 進化的影像診斷市場
• 顯影劑產品市場區隔
• 抗體
• 共軛放射性同位素
• 代謝生物標記
• 光探針
• 奈米粒子
• 標的顯影劑
• 活性化可能型顯影劑
• 顯影劑市場區隔的演進
• 疾病檢測
• 影像誘導藥物輸送
• 生理學流程的製圖
• 治療篩檢
• 治療評估
• 鑑別診斷
• 分子顯影劑和顯像模式
• MRI
• 光學成像
• PET
• SPECT
• 超音波
• 藥物類別
• Affibodies
• 抗體片段
• 免疫因素為目標的抗體
• 單株抗體
• 嵌合體單株抗體
• 奈米粒子
• 臨床應用
• 細胞凋亡
• 心臟病
• 血管新生
• 腺苷受體
• 血管內皮層生長因子受體
• 免疫學
• 自體免疫和發炎
• 代謝
• 糖尿病
• 神經學
• 澱粉樣肽
• 末梢苯二氮平類受體
• 多巴胺受體
• 代謝型麩胺酸
• 正腎上腺素轉運體
• P-糖蛋白質轉運體
• 血清素受體
• 血清素轉運體
• 大麻素受體
• 腫瘤學
• 雌激素受體
• 葡萄糖轉運體
• L型氨基酸轉運體
• 基質金屬蛋白酶
• 黑皮質素-1
• 前列腺特異性薄膜抗原(PSMA)
• 總和受體
• 生長抑制素受體
• 市場要素
• 指導，規則，規定
• FDA
• 企業簡介

Imaging agents that function at the Molecular and Cellular Level

The ability of molecular imaging agents to improve diagnostic and treatment capabilities is now driving a directed effort to develop new agents with enhanced specificity. To sense biological processes such as gene expression, angiogenesis, apoptosis or cell trafficking in vivo, imaging reporter agents that interact specifically with molecular targets and appropriate imaging systems are currently under development. Molecular imaging will greatly reduce the need for animal tissue sampling or human biopsy when studying the progression of a disease or the follow-up of a gene therapy. It has the advantage of being non-invasive, and because it can be repeated many times, it provides both spatial and temporal dimensions to the understanding of the gene expression of the disease or therapy.

What You Will Learn:

• Analyzes molecular imaging agents by category, target and method of detection, and assesses their capabilities, benefits, limitations and potential

• Examines evolving imaging market segments and their impact on the diagnostic imaging sector

• Analyzes key industry alliances and partnerships by imaging modality, and examines the impact of next-generation imaging candidates on future imaging markets

• Profiles market participants, their development activity and business strategies

• Evaluates the impact of economic, technology, and regulatory factors on the development and commercialization of emerging imaging agents

Table of Contents

• Executive Summary
• The Evolving Diagnostic Imaging Market
• Imaging Agent Product Segments
• Antibodies
• Conjugated Radioisotopes
• Metabolic Biomarkers
• Optical Probes
• Nanoparticles
• Targeted Imaging Agents
• Activatable Imaging Agents
• Evolution in Imaging Agent Market Segments
• Disease Detection
• Image-Guided Drug Delivery
• Physiological Process Mapping
• Therapeutic Screening
• Treatment Assessment
• Differential Diagnosis
• Molecular Imaging Agents & Imaging Modalities
• MRI
• Optical Imaging
• PET
• SPECT
• Ultrasound
• Agent Categories
• Affibodies
• Antibody Fragments
• Antibodies Targeting Immune Factors
• mAbs
• Chimeric mAbs
• Nanoparticles
• Clinical Applications
• Apoptosis
• Cardiology
• Angiogenesis
• Adenosine Receptors
• Vascular Endothelial Growth Factor Receptors
• Immunology
• Autoimmunity & Inflammation
• Metabolic
• Diabetes
• Neurology
• Amyloid Peptides
• Peripheral Benzodiazepine Receptors
• Dopamine Receptors
• Metabotropic Glutamate
• Norepinephrine Transporter
• P-glycoprotein Transporter
• Serotonin Receptors
• Serotonin Transporter
• Cannabinoid Receptors
• Oncology
• Estrogen Receptor
• Glucose Transporters
• L-Type Amino Acid Transporter
• Matrix Metalloproteinase
• Melanocortin-1
• Prostate-specific Membrane Antigen (PSMA)
• Sigma Receptors
• Somatostatin Receptors
• Market Factors
• Guidance, Rules and Regulations
• FDA
• Company Profiles